Profiling the kinome for drug discovery

Drug Discovery Today: Technologies

Volumn 3, Issue 3, 2006, Pages 269-276

  Yan, S Frank ^a   King, Frederick J ^a,b   Zhou, Yingyao ^a   Warmuth, Markus ^a   Xia, Gang ^a  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 701; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; NEXAVAR; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SORAFENIB; SPRYCEL; SUNITINIB; UNCLASSIFIED DRUG; VX 680; XL 999;

CANCER THERAPY; CARCINOGENESIS; DATA BASE; DECISION MAKING; DRUG DESIGN; DRUG MECHANISM; GENE EXPRESSION PROFILING; INFORMATION SCIENCE; MAMMAL; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TECHNOLOGY;

EID: 33750950088     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2006.09.012     Document Type: Review

References (38)

1. Bimbo A., et al. Systematic deletion analysis of fission yeast protein kinases. Eukaryot. Cell 4 (2005) 799-813
2. Manning G., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
3. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
4. Stoughton R.B., and Friend S.H. How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug Discov. 4 (2005) 345-350
5. Ley T.J., et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc. Natl. Acad. Sci. U S A 100 (2003) 14275-14280
6. Schnittger S., et al. D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. Genes Chromosomes Cancer 45 (2006) 332-337
7. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
8. Bardelli A., et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300 (2003) 949
9. Kling J. The search for a sequencing thoroughbred. Nat. Biotechnol. 23 (2005) 1333-1335
10. Carr S.A., et al. Mapping posttranslational modifications of proteins by MS-based selective detection: application to phosphoproteomics. Methods Enzymol. 405 (2005) 82-115
11. Corthals G.L., et al. Identification of phosphorylation sites using microimmobilized metal affinity chromatography. Methods Enzymol. 405 (2005) 66-81
12. Bose R., et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc. Natl. Acad. Sci. U S A 103 (2006) 9773-9778
13. Echeverri C.J., and Perrimon N. High-throughput RNAi screening in cultured cells: a user's guide. Nat. Rev. Genet. 7 (2006) 373-384
14. Moffat J., and Sabatini D.M. Building mammalian signalling pathways with RNAi screens. Nat. Rev. Mol. Cell. Biol. 7 (2006) 177-187
15. Fitzgerald K. RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes. Curr. Opin. Drug Discov. Devel. 8 (2005) 557-566
16. Yan, S.F. et al. Learning from the data: mining of large high-throughput screening databases. J. Chem. Inf. Model., doi:10.1021/ci060102u
17. Fabian M.A., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
18. Vieth M., et al. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov. Today 10 (2005) 839-846
19. Melnick J.S., et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl. Acad. Sci. U S A 103 (2006) 3153-3158
20. Vieth M., et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697 (2004) 243-257
21. Chuaqui C., et al. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening. J. Med. Chem. 48 (2005) 121-133
22. Steinert D.M., et al. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert Opin. Pharmacother. 6 (2005) 105-113
23. Yan S.F., et al. Novel statistical approach for primary high-throughput screening hit selection. J. Chem. Inf. Model. 45 (2005) 1784-1790
24. Buijsman R. Structural aspects of kinases and their inhibitors. In: Kubinyi H., and Müller G. (Eds). Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective (2004), Wiley-VCH 191-219
25. Weinstein J.N., et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275 (1997) 343-349
26. Covell D.G., et al. Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases. Proteins 59 (2005) 403-433
27. Zhou H., et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 20 (1998) 189-193
28. Gilbertson R.J., and Clifford S.C. PDGFRB is overexpressed in metastatic medulloblastoma. Nat. Genet. 35 (2003) 197-198
29. Daley G.Q., et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
30. Golub T.R., et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
31. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
32. Cappellen D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23 (1999) 18-20
33. Baxter E.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
34. Yamazaki H., et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol. Cell. Biol. 8 (1988) 1816-1820
35. Hirota S., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
36. Kiyoi H., et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 11 (1997) 1447-1452
37. Hermanson M., et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52 (1992) 3213-3219
38. Li J., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947